Teva (TEVA) Provides Update on Generic Aciphex Litigation
Down)
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the Southern District of New York has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Eisai's acid pump inhibitor Aciphex (Rabeprazole Sodium) Tablets, 20 mg. The Court found Eisai's U.S. Patent No. 5,045,552 enforceable.
Teva intends to appeal this decision immediately as well as the Court's decision granting to Eisai Summary Judgment of validity.
Teva intends to appeal this decision immediately as well as the Court's decision granting to Eisai Summary Judgment of validity.
You May Also Be Interested In
- Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
- QLT Inc. (QLTI) Issues Response to Nordic Biotech Notification on Board Nominees
- Apple's (AAPL) New iPad Shows Rapid Adoption in U.S.
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
